Skip to main navigation Skip to search Skip to main content

Proteomic-based stemness score measures oncogenic dedifferentiation and enables the identification of druggable targets

  • Clinical Proteomic Tumor Analysis Consortium
  • International Institute for Molecular Oncology
  • Medical University of Warsaw
  • Universidade de São Paulo
  • Mount Sinai Hospital
  • University of Texas MD Anderson Cancer Center
  • Icahn School of Medicine at Mount Sinai
  • Broad Institute
  • Massachusetts General Hospital Cancer Center
  • Washington University St. Louis
  • University of Miami
  • University of Michigan, Ann Arbor
  • University of Sannio
  • Henry Ford Health System
  • Nencki Institute of Experimental Biology of the Polish Academy of Sciences
  • Pomeranian Medical University in Szczecin
  • Baylor College of Medicine
  • Heliodor Swiecicki Clinical Hospital
  • National Institutes of Health

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article number100851
JournalCell Genomics
Volume5
Issue number6
DOIs
StatePublished - Jun 11 2025

ASJC Scopus Subject Areas

  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Genetics

Keywords

  • biomarkers
  • cancer
  • drug targets
  • kinase activity
  • machine learning
  • mass spectrometry
  • multiomics
  • proteomics
  • stemness
  • tumor plasticity

Fingerprint

Dive into the research topics of 'Proteomic-based stemness score measures oncogenic dedifferentiation and enables the identification of druggable targets'. Together they form a unique fingerprint.

Cite this